Heidi Overton's FDA nomination and rare disease policy
1 outlet · 0L · 0C · 1R
First reported
1 / 1
We're still gathering coverage of this story.
A neutral account and the side-by-side comparison are written once at least 2 outlets have reported it. Here is the coverage so far.
Left0 articles
No coverage yet.
Centre0 articles
No coverage yet.
- 2 Oct 16:00 First Washington ExaminerR The FDA’s new leadership must give rare disease patients a clearer path Opinion
- 5 Oct 15:00 +71h Washington ExaminerR Trump’s FDA is getting an overhaul. It’s time to crush China’s $11 billion illegal vape empire Opinion
Times are when each article was published, or when we first saw it if the outlet gave no time.